Investor Presentation Q1 2018

Investor Presentation First three months of 2018 Slide 42 Novo Nordisk holds a broad insulin portfolio with three generations of products covering the treatment cascade Novo Nordisk product portfolio includes three generations of insulin products Commercial focus depends on market maturity and market access situation Basal insulin Mix insulin GLP & basal Bolus combination insulin Commercial focus Volume strategy Value strategy New- generation insulin New- Tresiba® RyzodegⓇ XultophyⓇ Fiasp® generation insulin Differentiation Modern insulin Levemir® NovoMixⓇ NovoLogⓇ Modern insulin Familiarity Human insulin Insulatard® Mixtard® ActrapidⓇ Human insulin Affordability changing diabetes® novo nordisk

View entire presentation